This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldhaber, S. Z. Search for Related Content PubMed PubMed Citation Articles by Goldhaber, S. Z. Pubmed/NCBI databases Substance via MeSH Hazardous Substances DB HEPARIN Medline Plus Health Information Pulmonary Embolism

(Circulation. 2001;104:2876.)
© 2001 American Heart Association, Inc.

Editorial

Thrombolysis in Pulmonary Embolism

A Large-Scale Clinical Trial Is Overdue

Samuel Z. Goldhaber, MD

From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.

Correspondence to Samuel Z. Goldhaber, MD, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis St, Tower 3B, Boston, MA 02115. E-mail sgoldhaber@partners.org

Key Words: Editorials • embolism • pulmonary heart disease • thrombolysis • thrombus • veins

Thrombolysis for acute pulmonary embolism (PE) remains a debatable indication because inadequate data exist to provide definitive management guidelines.¹ As cardiologists, we have relied on large-scale randomized clinical trials to determine that thrombolysis benefits patients with ST-segment elevation acute myocardial infarction (MI). Yet, no clinical investigations similar in scope have been undertaken for pulmonary thromboembolism, even though this illness afflicts 100 000 patients annually in the United States² and has a high case fatality rate.³

Intuitively, thrombolysis makes sense, especially for massive PE with cardiogenic shock. Nevertheless, only one small randomized controlled trial of 8 patients has tested this strategy among these desperately ill PE patients.⁴ The thrombolytic regimen was streptokinase, given in the MI dose of 1 500 000 U administered over a period of 1 hour. All 4 patients receiving thrombolysis plus heparin survived, whereas none were treated successfully with anticoagulation alone. Although the investigators originally intended to enroll 40 patients, they halted their trial for ethical reasons after the first 8 patients yielded such disparate results between the 2 groups. Despite these dramatic differences between the 2 groups, we should not craft treatment policy on the basis of an 8-patient trial.

Shockingly, there are only 9 randomized trials of PE thrombolysis versus heparin, with a total of <500 patients.^4–13 Only 2 of these trials have enrolled >100 patients. The first trial, the Urokinase Pulmonary Embolism Trial, enrolled 160 patients who were randomized to thrombolysis plus heparin or heparin alone.⁵ This has been the largest trial to date. . . . [Full Text of this Article]

This article has been cited by other articles:

				T. Capstick and M. T. Henry Efficacy of thrombolytic agents in the treatment of pulmonary embolism Eur. Respir. J., November 1, 2005; 26(5): 864 - 874. [Abstract] [Full Text] [PDF]

				S. Z. Goldhaber Thrombolytic Therapy for Patients With Pulmonary Embolism Who Are Hemodynamically Stable But Have Right Ventricular Dysfunction: Pro Arch Intern Med, October 24, 2005; 165(19): 2197 - 2199. [Full Text] [PDF]

				S. Z. Goldhaber Rebuttal Arch Intern Med, October 24, 2005; 165(19): 2204 - 2204. [Full Text] [PDF]

				G. Thabut and D. Logeart Rebuttal Arch Intern Med, October 24, 2005; 165(19): 2204 - 2205. [Full Text] [PDF]

				S. Wan, D. J. Quinlan, G. Agnelli, and J. W. Eikelboom Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism: A Meta-Analysis of the Randomized Controlled Trials Circulation, August 10, 2004; 110(6): 744 - 749. [Abstract] [Full Text] [PDF]

				M. ten Wolde, M. Sohne, E. Quak, M. R. Mac Gillavry, and H. R. Buller Prognostic Value of Echocardiographically Assessed Right Ventricular Dysfunction in Patients With Pulmonary Embolism Arch Intern Med, August 9, 2004; 164(15): 1685 - 1689. [Abstract] [Full Text] [PDF]

				J. W. Kreit The Impact of Right Ventricular Dysfunction on the Prognosis and Therapy of Normotensive Patients With Pulmonary Embolism Chest, April 1, 2004; 125(4): 1539 - 1545. [Abstract] [Full Text] [PDF]

				N. Kucher, C.M. Luder, T. Dornhofer, S. Windecker, B. Meier, and O.M. Hess Novel management strategy for patients with suspected pulmonary embolism Eur. Heart J., February 2, 2003; 24(4): 366 - 376. [Abstract] [Full Text] [PDF]

				G. Thabut, D. Thabut, R. P. Myers, B. Bernard-Chabert, R. Marrash-Chahla, H. Mal, and M. Fournier Thrombolytic therapy of pulmonary embolism: A meta-analysis J. Am. Coll. Cardiol., November 6, 2002; 40(9): 1660 - 1667. [Abstract] [Full Text] [PDF]

				S. Konstantinides, A. Geibel, G. Heusel, F. Heinrich, W. Kasper, and the Management Strategies and Prognosis of Pulmona Heparin plus Alteplase Compared with Heparin Alone in Patients with Submassive Pulmonary Embolism N. Engl. J. Med., October 10, 2002; 347(15): 1143 - 1150. [Abstract] [Full Text] [PDF]

				L. Aklog, C. S. Williams, J. G. Byrne, and S. Z. Goldhaber Acute Pulmonary Embolectomy: A Contemporary Approach Circulation, March 26, 2002; 105(12): 1416 - 1419. [Abstract] [Full Text] [PDF]